L’Oréal’s CEO says the growing use of GLP-1 weight-loss medicines is starting to affect beauty and skincare demand, particularly for concerns that can arise after rapid weight loss. Speaking during an investor call after the company’s quarterly results, Nicolas Hieronimus describes GLP-1 adoption as an important development for the beauty industry.
L’Oréal says it already has skincare products aimed at issues such as skin sagging, and it is conducting separate studies involving GLP-1 users to assess potential product needs for this expanding consumer segment. The reports also note that experts attribute “Ozempic face” type changes to rapid weight-loss itself rather than a direct skin effect of the drugs. Other companies, including Galderma and Natura, are described as exploring similar opportunities, with the BBC emphasizing the significance of the phenomenon to L’Oréal’s business.
Across outlets, the differing emphasis is mainly on framing: Free Press Journal focuses more on product and study efforts and industry context, while the BBC foregrounds the CEO’s assessment that GLP-1s are a major factor for the company.